Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/2122
Full metadata record
DC FieldValueLanguage
dc.contributorTie, E.en_US
dc.contributorDinh, D.en_US
dc.contributorChan, W.en_US
dc.contributorClark, D.en_US
dc.contributorAjani, A.en_US
dc.contributorBrennan, A.en_US
dc.contributorDagan, M.en_US
dc.contributorCohen, N.en_US
dc.contributorOqueli, Ernestoen_US
dc.contributorFreeman, M.en_US
dc.contributorHiew, C.en_US
dc.contributorShaw, J.en_US
dc.contributorReid, C.en_US
dc.contributorKaye, D.en_US
dc.contributorStub, D.en_US
dc.contributorDuffy, S.en_US
dc.date.accessioned2023-02-20T05:18:15Z-
dc.date.available2023-02-20T05:18:15Z-
dc.date.issued2022-
dc.identifier.govdoc02056en_US
dc.identifier.urihttp://hdl.handle.net/11054/2122-
dc.description.abstractMyocardial infarction complicated by cardiogenic shock (MI-CS) has a poor prognosis, even with early revascularization. Previously, intra-aortic balloon pump (IABP) use was thought to improve outcomes, but the IABP-SHOCK-II (Intra-aortic Balloon Pump in Cardiogenic Shock-II study) trial found no survival benefit. We aimed to determine the trends in IABP use in patients who underwent percutaneous intervention over time. Data were taken from patients in the Melbourne Interventional Group registry (2005 to 2018) with MI-CS who underwent percutaneous intervention. The primary outcome was the trend in IABP use over time. The secondary outcomes included 30-day mortality and major adverse cardiovascular and cerebrovascular events (MACCEs). Of the 1,110 patients with MI-CS, IABP was used in 478 patients (43%). IABP was used more in patients with left main/left anterior descending culprit lesions (62% vs 46%), lower ejection fraction (<35%; 18% vs 11%), and preprocedural inotrope use (81% vs 73%, all p <0.05). IABP use was associated with higher bleeding (18% vs 13%) and 30-day MACCE (58% vs 51%, both p <0.05). The rate of MI-CS per year increased over time; however, after 2012, there was a decrease in IABP use (p <0.001). IABP use was a predictor of 30-day MACCE (odds ratio 1.6, 95% confidence interval 1.18 to 2.29, p = 0.003). However, IABP was not associated with in-hospital, 30-day, or long-term mortality (45% vs 47%, p = 0.44; 46% vs 50%, p = 0.25; 60% vs 62%, p = 0.39). In conclusion, IABP was not associated with reduced short- or long-term mortality and was associated with increased short-term adverse events. IABP use is decreasing but is predominately used in sicker patients with greater myocardium at risk.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2023-02-08T04:15:40Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2023-02-20T05:18:15Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2023-02-20T05:18:15Z (GMT). No. of bitstreams: 0 Previous issue date: 2022en
dc.titleTrends in intra-aortic balloon pump use in cardiogenic shock after the SHOCK-II trial.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.contributor.corpauthorMelbourne Interventional Group Investigatorsen_US
dc.bibliographicCitation.titleAmerican Journal of Cardiologyen_US
dc.bibliographicCitation.volume191en_US
dc.bibliographicCitation.stpage125en_US
dc.bibliographicCitation.endpage132en_US
dc.subject.healththesaurusPERCUTANEOUS MECHANICAL CIRCULATORY SUPPORTen_US
dc.subject.healththesaurusINTRA-AORTIC BALLOON PUMPen_US
dc.subject.healththesaurusCARDIOGENIC SHOCKen_US
dc.subject.healththesaurusMYOCARDIAL INFARCTIONen_US
dc.subject.healththesaurusPERCUTANEOUS CORONARY INTERVENTIONen_US
dc.subject.healththesaurusOUTCOMESen_US
dc.identifier.doihttps://doi.org/10.1016/j.amjcard.2022.12.019en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.